4.7 Article

Incidence and impact of anticoagulation-associated abnormal menstrual bleeding in women after venous thromboembolism

期刊

BLOOD
卷 140, 期 16, 页码 1764-1773

出版社

AMER SOC HEMATOLOGY
DOI: 10.1182/blood.2022017101

关键词

-

资金

  1. Bayer AG
  2. Boehringer Ingelheim
  3. Bristol-Myers Squibb/Pfizer
  4. Daiichi Sankyo
  5. DOASENSE
  6. Alexion
  7. MSD
  8. Italian Ministry of Health
  9. Leo-Pharma foundation
  10. Rovi
  11. Roche
  12. Bayer
  13. GSK
  14. Actelion
  15. Bristol-Myers Squibb
  16. Boehringer-Ingelheim
  17. Leo Pharma
  18. Daiichi-Sankyo
  19. Netherlands Organisation for Health Research and Development
  20. Dutch Thrombosis Association
  21. Dutch Heart Foundation
  22. Horizon Europe Program

向作者/读者索取更多资源

Preliminary data and clinical experience suggest an increased risk of abnormal uterine bleeding (AUB) in women of reproductive age treated with anticoagulants, but there is a lack of solid data. In a study involving 98 women diagnosed with acute venous thromboembolism (VTE), 2 out of 3 women experienced AUB during anticoagulation treatment, with a significant negative impact on their quality of life (QoL).
Preliminary data and clinical experience have suggested an increased risk of abnormal uterine bleeding (AUB) in women of reproductive age treated with anticoagulants, but solid data are lacking. The TEAM-VTE study was an international multicenter prospective cohort study in women aged 18 to 50 years diagnosed with acute venous thromboembolism (VTE). Menstrual blood loss was measured by pictorial blood loss assessment charts at baseline for the last menstrual cycle before VTE diagnosis and prospectively for each cycle during 3 to 6 months of follow-up. AUB was defined as an increased score on the pictorial blood loss assessment chart (>100 or >150) or self-reported AUB. AUB-related quality of life (QoL) was assessed at baseline and the end of follow-up using the Menstrual Bleeding Questionnaire. The study was terminated early because of slow recruitment attributable to the COVID-19 pandemic. Of the 98 women, 65 (66%) met at least one of the 3 definitions of AUB during follow-up (95% confidence interval [CI], 57%-75%). AUB occurred in 60% of women (36 of 60) without AUB before VTE diagnosis (new-onset AUB; 95% CI, 47%-71%). Overall, QoL decreased over time, with a mean Menstrual Bleeding Questionnaire score increase of 5.1 points (95% CI, 2.2-7.9), but this decrease in QoL was observed only among women with new-onset AUB. To conclude, 2 of every 3 women who start anticoagulation for acute VTE experience AUB, with a considerable negative impact on QoL. These findings should be a call to action to increase awareness and provide evidence-based strategies to prevent and treat AUB in this setting.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据